Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written informed consent to participate in the study~2. Willing and able to comply with all study requirements and instructions of the site study staff~3. Male or female, 40 years to 85 years old (inclusive)~4. Ambulatory~5. Index knee must have been symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II-IV) acquired at Screening~6. Moderate to moderately severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Pain Subscale) assessed at Screening and confirmed at randomization~7. Moderate to moderately severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drugs \[NSAIDs\], which have not changed in the 4 weeks prior to Screening, had been used)~8. No analgesia taken 24 hours before efficacy measure~Exclusion Criteria:~1. As a result of medical review and screening investigation, the Principal Investigator considered the subject unfit for the study~2. Previous Ampion injection~3. Known clinically significant liver abnormality (eg, cirrhosis, transplant, etc.)~4. History of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin was not an exclusion criterion)~5. History of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)~6. Presence of tense effusions in the index knee~7. Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the index knee, as assessed locally by the Principal Investigator~8. Isolated patella femoral syndrome, also known as chondromalacia in the index knee~9. Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (eg, cancer, congenital defects, spine OA)~10. Major injury to the index knee within the 12 months prior to Screening~11. Severe hip OA ipsilateral to the index knee~12. Any pain that could interfere with the assessment of index knee pain (eg, pain in any other part of the lower extremities, pain radiating to the knee)~13. Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to treatment or likely to be changed during the duration of the study~14. Use of any of the following medications:~    * IA-injected pain medications in the index knee during the study~   * Analgesics containing opioids (NSAIDs were allowed at the levels preceding the study and acetaminophen was available as rescue medication during the study from the provided supply)~   * Topical prescription treatment on the index knee during the study~   * Significant anticoagulant therapy (eg, heparin or enoxaparin) during the study (aspirin and clopidogrel were allowed)~   * Systemic treatments that could interfere with safety or efficacy assessments during the study~   * Immunosuppressants~   * Corticosteroids \>10 mg prednisolone equivalent per day or corticosteroids at doses ≤10 mg prednisolone equivalent that had been changed during the study~15. Any human albumin treatment in the 3 months before randomization

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AMPION™ 4 mL dose (Type: EXPERIMENTAL): 4 mL injection of Ampion
- Placebo 4 mL dose (Type: PLACEBO_COMPARATOR): 4 mL injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).